

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ZJ

中基長壽科學

ZHONG JI LONGEVITY SCIENCE

Zhong Ji Longevity Science Group Limited

中基長壽科學集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 767)

**CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR;
CHANGE IN COMPOSITION OF BOARD COMMITTEES; AND
COMPLIANCE WITH RULE 13.92 OF THE LISTING RULES**

The Board hereby announces the following changes with effect from 27 November 2025:

- (1) Mr. Lee See Barry has resigned as an independent non-executive Director, and has ceased to be the chairman of the audit committee and a member of each of the remuneration committee, the nomination committee, the risk management committee and the share award committee of the Board; and
- (2) Ms. Wang Huijuan has been appointed as an independent non-executive Director and a member of each of the audit committee, the remuneration committee, the nomination committee, the risk management committee and the share award committee of the Board; and
- (3) Mr. Huang Jiang has been appointed as the chairperson of the audit committee.

The board (the “**Board**”) of directors (the “**Director(s)**”) of Zhong Ji Longevity Science Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces the following changes with effect from 27 November 2025.

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

Mr. Lee See Barry (“**Mr. Lee**”) has tendered his resignation as an independent non-executive Director with effect from 27 November 2025 due to his devotion to his personal family affairs and other business commitments. Mr. Lee has confirmed that he has no disagreement with the Board and there are no other matters in respect of his resignation as an independent non-executive Director that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). The Board would like to take this opportunity to express its gratitude and appreciation to Mr. Lee for his valuable contribution to the Company during his tenure of office.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board is also pleased to announce that Ms. Wang Huijuan (“**Ms. Wang**”) has been appointed as an independent non-executive Director with effect from 27 November 2025.

The biographical details of Ms. Wang are set out as follows:

Ms. Wang Huijuan, aged 48, graduated from the Performance Department of Beijing Film Academy in 2001 and is an actor with the China National Theatre, a member of the Actors Working Committee of the China Television Artists Association, and a member of the 10th All-China Youth Federation. She is also a director and goodwill ambassador of the Qiming Public Welfare Foundation, a goodwill ambassador of the Zhongai Special Fund, and a goodwill ambassador of the China Charities Aid Foundation For Children. She has extensive experience and talent in cultural media and charitable work.

As at the date of this announcement, Ms. Wang has confirmed that she (i) does not have any relationship with any Director, senior management, or substantial or controlling shareholder (as defined in the Listing Rules) of the Company; (ii) does not have, and is not deemed to have, any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (iii) did not hold any directorship in other listed companies in Hong Kong or overseas in the past three years; and (iv) does not hold any other positions within the Company and other members of the Group.

Ms. Wang has entered into an appointment letter with the Company with an initial term of three years. Ms. Wang is subject to retirement by rotation and re-election (if applicable) at the annual general meeting at least once every three years in accordance with the bye-laws of the Company and the Corporate Governance Code set out in Appendix C1 to the Listing Rules. She is entitled to receive a director’s fee of HK\$20,000 per month, which is determined by the remuneration committee of the Company and the Board, and is subject to annual review with reference to the prevailing market conditions, her duties and responsibilities and the time she spent on the affairs of the Company.

Ms. Wang confirmed that she (i) met the independence criteria as set out in Rule 3.13 of the Listing Rules; (ii) has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined under the Listing Rules) of the Company; and (iii) there are no other factors that may affect her independence at the time of her appointment.

Before Ms. Wang's appointment became effective, on 27 November 2025, Ms. Wang had obtained legal advice from a firm of solicitors qualified to advise on Hong Kong law referred to in Rule 3.09D of the Listing Rules and had confirmed that she understood her obligations as a Director and the possible consequences of making a false declaration or giving false information to the Stock Exchange. As at the date of this announcement and save as disclosed above, Ms. Wang confirmed that there are no other matters in relation to her appointment that need to be brought to the attention of the Shareholders or the Stock Exchange, and there is no other information that should be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules. The Board would like to take this opportunity to welcome Ms. Wang for joining the Board.

CHANGE IN COMPOSITION OF BOARD COMMITTEES

Following the resignation of Mr. Lee as an independent non-executive Director, Mr. Lee has ceased to be the chairman of the audit committee (the “**Audit Committee**”) and a member of each of the remuneration committee, the nomination committee, the risk management committee and the share award committee of the Board. Simultaneously, with effect from 27 November 2025, Ms. Wang has been appointed as a member of each of the Audit Committee, the remuneration committee, the nomination committee, the risk management committee and the share award committee of the Board, while Mr. Huang Jiang has been appointed as the chairman of the Audit Committee.

COMPLIANCE WITH RULE 13.92 OF THE LISTING RULES

Pursuant to Rule 13.92 of the Listing Rules, the Stock Exchange will not consider diversity to be achieved for a single gender board. Code Provision B.3.5 of the Corporate Governance Code as set out in Appendix C1 (“**Code Provision B.3.5**”) of the Listing Rules states that the Company should appoint at least one director of a different gender to the nomination committee. Following the appointment of Ms. Wang as an independent non-executive Director with effect from 27 November 2025, the Company will comply with the board diversity requirement under Rule 13.92 of the Listing Rules and the requirement under the Code Provision B.3.5.

By order of the Board

Zhong Ji Longevity Science Group Limited

Yan Li

Chairman, Chief Executive Officer and Executive Director

Hong Kong, 27 November 2025

As at the date of this announcement, the Directors are:

Executive Directors

Mr. Yan Li (*Chairman and Chief
Executive Officer*)

Mr. Li Xiaoshuang

Independent Non-executive Directors

Mr. Huang Jiang

Prof. Huang Cibo

Ms. Wang Huijuan

Non-executive Directors

Dr. He Yiwu

Mr. Lyu Changshang

In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.